APP and Alzheimer disease: Our present study evaluates the effect of a chronic administration of DXI in the inflammatory process surrounded AD development, but also in the metabolic alterations such as weight gain, hyperglycemia and insulin resistance induced by HFD intake in APP/PS1 mice.